Sanofi: Multiple Sclerosis trials

The registry lists 44 Multiple Sclerosis studies with Sanofi as lead sponsor. 3 are open to participants now and 24 have results posted.

Phase 1 5Phase 2 13Phase 3 18Phase 4 5No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple SclerosisNot yet recruitingNCT07930624Phase 3
• A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-world SettingRecruitingNCT07898371
• Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisRecruitingNCT07325292Phase 3
• A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple SclerosisTerminatedNCT05630547Phase 2Results posted
• Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisActive, not recruitingNCT04879628Phase 2Results posted
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)CompletedNCT04410991Phase 3Results posted
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)CompletedNCT04410978Phase 3Results posted
• Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple SclerosisCompletedNCT03996291Phase 2Results posted
• Dose-finding Study for SAR442168 in Relapsing Multiple SclerosisCompletedNCT03889639Phase 2Results posted
• Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving LemtradaCompletedNCT03784898Phase 4Results posted
• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMTTerminatedNCT03368664Phase 3Results posted
• Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple SclerosisCompletedNCT02201108Phase 3Results posted
• Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsCompletedNCT01895335Phase 4Results posted
• Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on TeriflunomideCompletedNCT01403376Phase 2Results posted
• Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-betaTerminatedNCT01252355Phase 3Results posted
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of AlemtuzumabCompletedNCT00930553Phase 3Results posted
• A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple SclerosisCompletedNCT00883337Phase 3Results posted
• Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple SclerosisCompletedNCT00811395Phase 2Results posted
• Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple SclerosisCompletedNCT00803049Phase 3Results posted
• An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple SclerosisCompletedNCT00751881Phase 3Results posted
• Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple SclerosisCompletedNCT00622700Phase 3Results posted
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study TwoCompletedNCT00548405Phase 3Results posted
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study OneCompletedNCT00530348Phase 3Results posted
• Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple SclerosisCompletedNCT00489489Phase 2Results posted
• Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple SclerosisCompletedNCT00475865Phase 2Results posted
• Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple SclerosisCompletedNCT00134563Phase 3Results posted
• A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple SclerosisCompletedNCT00050778Phase 2Results posted
• Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisActive, not recruitingNCT06141486Phase 3
• Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisActive, not recruitingNCT06141473Phase 3
• Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult ParticipantsCompletedNCT06106074Phase 1
• Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult SubjectsCompletedNCT06064539Phase 1
• Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male ParticipantsCompletedNCT04982991Phase 1
• Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 WeeksCompletedNCT04410965Phase 4
• Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male SubjectsCompletedNCT04171310Phase 1
• To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT03856619Phase 4
• LEMTRADA Pregnancy Registry in Multiple SclerosisCompletedNCT03774914
• An Observational Study on Teriflunomide-exposed PregnanciesCompletedNCT03198351
• A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese VolunteersCompletedNCT02046629Phase 1
• Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple SclerosisCompletedNCT01863888Phase 3
• Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With RelapsesCompletedNCT01487096Phase 2
• Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple SclerosisCompletedNCT00811902Phase 2
• Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple SclerosisCompletedNCT00772525Phase 2
• FOCUS Fatigue Outcome in Copaxone USersCompletedNCT00267319Phase 4
• Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With RelapsesCompletedNCT00228163Phase 2